{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:01:04Z","timestamp":1791172864950,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Yttrium\u201090 FF\u201021101 (<jats:sup>90<\/jats:sup>Y\u2013FF\u201021101) is a radiopharmaceutical that targets P\u2010cadherin as a therapy against solid tumors. A previously reported, first\u2010in\u2010human study determined that a dose of 25 mCi\/m<jats:sup>2<\/jats:sup> was safe, and a patient with clear cell carcinoma of the ovary achieved a complete response. In this article, the authors report the results of <jats:sup>90<\/jats:sup>Y\u2013FF\u201021101 treatment in an ovarian carcinoma expansion cohort and in patients with selected solid tumors who had known high P\u2010cadherin expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The trial was conducted as an open\u2010label study in patients with advanced\/metastatic disease. Radiologic response and safety were evaluated in patients who received 25 mCi\/m<jats:sup>2<\/jats:sup> intravenously once every three cycles of 28 days until they developed progressive disease. Evaluation of the ovarian cohort was conducted in a Simon two\u2010stage manner to determine further enrollment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010seven patients (20 with ovarian carcinoma) were enrolled and treated. Patients who had ovarian and solid tumors had received a median of five and three prior therapies, respectively. No complete or partial responses were observed, so the trial was ended. The median progression\u2010free survival was 118 days for the ovarian cohort and 55 days for the solid\u2010tumor cohort. The most common treatment\u2010related adverse events were thrombocytopenia (40%) and neutropenia (54%). One patient each developed fatal veno\u2010occlusive disease and intracranial hemorrhage. Patients with higher P\u2010cadherin levels remained on the study longer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p><jats:sup>90<\/jats:sup>Y\u2013FF\u201021101 did not meet the predefined efficacy criteria, and adverse events were consistent with <jats:sup>90<\/jats:sup>Y agents. These data may assist in the development of other P\u2010cadherin\u2013directed therapies (ClinicalTrials.gov identifier NCT02454010).<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.35680","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T03:28:09Z","timestamp":1735874889000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A trial of radiolabeled antibody yttrium\u201090\u2013FF\u201021101 for the treatment of advanced ovarian and other cancers"],"prefix":"10.1002","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-9894","authenticated-orcid":false,"given":"Devalingam","family":"Mahalingam","sequence":"first","affiliation":[{"name":"Northwestern University Feinberg School of Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7724-7728","authenticated-orcid":false,"given":"Taofeek K.","family":"Owonikoko","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Delpassand","sequence":"additional","affiliation":[{"name":"Excel Diagnostics and Nuclear Oncology Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Mulcahy","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Kalyan","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Ulahannan","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center University of Oklahoma Health Sciences Center\/Sarah Cannon Research Institute  Oklahoma City Oklahoma USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kin","family":"Cheung","sequence":"additional","affiliation":[{"name":"FUJIFILM Pharmaceuticals USA, Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasayuki","family":"Izumi","sequence":"additional","affiliation":[{"name":"FUJIFILM Pharmaceuticals USA, Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0118-2224","authenticated-orcid":false,"given":"Mary","family":"Johansen","sequence":"additional","affiliation":[{"name":"FUJIFILM Pharmaceuticals USA, Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Madden","sequence":"additional","affiliation":[{"name":"FUJIFILM Pharmaceuticals USA, Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0584-5200","authenticated-orcid":false,"given":"Susumu","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"FUJIFILM Pharmaceuticals USA, Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Subach","sequence":"additional","affiliation":[{"name":"FUJIFILM Pharmaceuticals USA, Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"FUJIFILM Pharmaceuticals USA, Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7407-6727","authenticated-orcid":false,"given":"David S.","family":"Wages","sequence":"additional","affiliation":[{"name":"FUJIFILM Pharmaceuticals USA, Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Wheeler","sequence":"additional","affiliation":[{"name":"FUJIFILM Pharmaceuticals USA, Inc  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center University of Oklahoma Health Sciences Center\/Sarah Cannon Research Institute  Oklahoma City Oklahoma USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010020\u20100073\u20109"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061733"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.57177"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2010023\u201000516\u2010z"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.167247"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.2007.112"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00989"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2012.05.002"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201020\u20100037"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.Mct\u201021\u20100652"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.845417"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010022\u201004781\u20103"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.245837"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1040\u20108428(00)00136\u20100"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201008\u20101086"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943\u2010015\u20100448\u20104"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.1075"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701528517"},{"key":"e_1_2_9_21_1","volume-title":"Cancer: Principles and Practice of Oncology","author":"Lawrence TS","year":"2008"},{"issue":"10","key":"e_1_2_9_22_1","first-page":"3855","article-title":"A phase I radioimmunotherapy trial evaluating 90yttrium\u2010labeled anti\u2010carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA\u2010producing malignancies","volume":"6","author":"Wong JYC","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201010\u20102579"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23339"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.85"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010020\u201000975\u20102"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010022\u201000652\u2010y"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720111793663651"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215570"},{"issue":"8","key":"e_1_2_9_30_1","first-page":"3095","article-title":"High\u2010dose therapy with 90Yttrium\u2010labeled monoclonal antibody CC49: a phase I trial","volume":"6","author":"Tempero M","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds203"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2019.2992"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108022"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.34"},{"key":"e_1_2_9_35_1","article-title":"Preclinical evaluation of cadherin 3 (CDH3)\u2010targeted alpha radiopharmaceutical therapy, 225Ac\u2010PPMX\u2010T002 for the treatment of solid cancer [abstract]","author":"Hagiwara S","year":"2024","journal-title":"Paper presented at: 37th Annual Congress of the European Association of Nuclear Medicine (EANM)"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:59:10Z","timestamp":1760266750000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/cncr.35680"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35680","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e35680"}}